Generation and functional characterization of arylamine N-acetyltransferase Nat1/Nat2 double-knockout mice

Molecular Pharmacology

Volumn 64, Issue 1, 2003, Pages 170-179

  Sugamori, Kim S ^a,e   Wong, Sharon ^a   Gaedigk, Andrea ^a,b   Yu, Violeta ^a,c   Abramovici, Hanan ^a,d   Rozmahel, Richard ^a   Grant, Denis M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; ARYLAMINE ACETYLTRANSFERASE; SULFADIMIDINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CATALYSIS; CONTROLLED STUDY; CYTOSOL; DRUG ACETYLATION; DRUG BLOOD LEVEL; EMBRYO CELL; FEMALE; GENE TARGETING; GENOTYPE; KNOCKOUT MOUSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILD TYPE;

ACETYLATION; ACETYLTRANSFERASES; AMINO ACID TRANSPORT SYSTEMS; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; CARRIER PROTEINS; FEMALE; GENOTYPE; ISOENZYMES; MALE; MICE; MICE, KNOCKOUT;

EID: 0037561531     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.1.170     Document Type: Article

References (43)

1. Boukouvala S, Price N, and Sim E (2002) Identification and functional characterization of novel polymorphisms associated with the genes for arylamine N-acetyltransferases in mice. Pharmacogenetics 12:385-394.
2. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, Doehmer J, Ward JM, Jefcoate CR, and Gonzalez FJ (1999) Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA 96:1977-1982.
3. S slow acetylator congenic mice. Drug Metab Dispos 21:1057-1063.
4. Dupret JM, Goodfellow GH, Janezic SA, and Grant DM (1994) Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli. J Biol Chem 269:26830-26835.
5. Eaton DL, Gallagher EP, Bammler TK, and Kunze KL (1995) Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics 5:259-274.
6. Estrada L, Kanelakis KC, Levy GN, and Weber WW (2000) Tissue- and gender-specific expression of N-acetyltransferase 2 (Nat2*) during development of the outbred mouse strain CD-1. Drug Metab Dispos 28:139-146.
7. Estrada-Rodgers L, Levy GN, and Weber WW (1998) Substrate selectivity of mouse N-acetyltransferases 1, 2 and 3 expressed in COS-1 cells. Drug Metab Dispos 26:502-505.
8. Fretland AJ, Doll MA, Gray K, Feng Y, and Hein DW (1997) Cloning, sequencing, and recombinant expression of NAT1, NAT2 and NAT3 derived from the C3H/HeJ (rapid) and A/HeJ (slow) acetylator inbred mouse: functional characterization of the activation and deactivation of aromatic amine carcinogens. Toxicol Appl Pharmacol 142:360-366.
9. Gonzalez FJ and Kimura S (2003) Study of P450 function using gene knockout and transgenic mice. Arch Biochem Biophys 409:153-158.
10. Grant DM, Goodfellow GH, Sugamori K, and Durette K (2000) Pharmacogenetics of the human arylamine N-acetyltransferases. Pharmacology 61:204-211.
11. Hein DW (2002) Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507:65-77.
12. Hein DW, Doll MA, Fretland AJ, Gray K, Deitz AC, Feng Y, Jiang W, Rustan TD, Satran SL, and Wilkie TR Sr. (1997) Rodent models of the human acetylation polymorphism: comparisons of recombinant acetyltransferases. Mutat Res 376:101-106.
13. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangiu NA, and Feng Y (2000) Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 9:29-42.
14. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ, and Grant DM (1993) Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14:1633-1638.
15. Hughes NC, Janezic SA, McQueen KL, Jewett MA, Castranio T, Bell DA, and Grant DM (1998) Identification and characterization of variant alleles of human acetyltransferase NAT1 with defective function using p-aminosalicylate as an in-vivo and in-vitro probe. Pharmacogenetics 8:55-66.
16. Kelly SL and Sim E (1994) Arylamine N-acetyltransferase in BALB/c mice: identification of a novel mouse isoenzyme by cloning and expression in vitro. Biochem J 302:347-353.
17. Kimura S, Kawabe M, Ward JM, Morishima H, Kadlubar FF, Hammons GJ, Fernandez-Salguero P, and Gonzalez FJ (1999) CYP1A2 is not the primary enzyme responsible for 4-aminobiphenyl-induced hepatocarcinogenesis in mice. Carcinogenesis 20:1825-1830.
18. Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, and Gonzalez FJ (1996) Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem 271:12063-12067.
19. Leff MA, Epstein PN, Doll MA, Fretland AJ, Devanaboyina US, Rustan TD, and Hein DW (1999) Prostate-specific human N-acetyltransferase 2 (NAT2) expression in the mouse. J Pharmacol Exp Ther 290:182-187.
20. Levy GN, Martell KJ, and Weber WW (1993) Polymorphic N-acetylation of 2-aminofluorene by cell-free colon extracts from inbred mice. Pharmacogenetics 3:71-76.
21. Levy GN and Weber WW (1989) 2-Aminofluorene-DNA adduct formation in acetylator congenic mouse lines. Carcinogenesis 10:705-709.
22. Levy GN and Weber WW (1992) 2-Aminofluorene-DNA adducts in mouse urinary bladder: effect of age, sex and acetylator phenotype. Carcinogenesis 13:159-164.
23. Lin HJ, Probst-Hensch NM, Hughes NC, Sakamoto GT, Louie AD, Kau IH, Lin BK, Lee DB, Lin J, Frankl HD, et al. (1998) Variants of N-acetyltransferase NAT1 and a case-control study of colorectal adenomas. Pharmacogenetics 8:269-281.
24. Martell KJ, Vatsis KP, and Weber WW (1991) Molecular genetic basis of rapid and slow acetylation in mice. Mol Pharmacol 40:218-227.
25. Mitchell MK, Futscher BW, and McQueen CA (1999) Developmental expression of N-acetyltransferases in C57BL/6 mice. Drug Metab Dispos 27:261-264.
26. Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, and Gonzalez FJ (1999) Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene. J Biol Chem 274:23963-23968.
27. Nebert DW and Russell DW (2002) Clinical importance of the cytochrome P450. Lancet 360:1155-1162.
28. Payton M, Smelt V, Upton A, and Sim E (1999) A method for genotyping murine arylamine N-acetyltransferase type 2 (NAT2): a gene expressed in preimplantation embryonic stem cells encoding an enzyme acetylating the folate catabolite p-aminobenzoylglutamate. Biochem Pharmacol 58:779-785.
29. Schieferstein GJ, Littlefield NA, Gaylor DW, Sheldon WG, and Burger GT (1985) Carcinogenesis of 4-aminobiphenyl in BALB/cStCrlfC3Hf/Nctr mice. Eur J Cancer Clin Oncol 21:865-873.
30. Shen AL, O'Lear KA, and Kasper CB (2002) Association of multiple developmental defects and embryonic lethality with loss of microsomal NADPH-cytochrome P450 oxidoreductase. J Biol Chem 277:6536-6541.
31. Shertzer HG, Dalton TP, Talaska G, and Nebert DW (2002) Decrease in 4-aminobiphenyl-induced methemoglobinemia in Cyp1a2(-/-) knockout mice. Toxicol Appl Pharmacol 181:32-37.
32. Sills RC, French JE, and Cunningham ML (2001) New models for assessing carcinogenesis: an ongoing process. Toxicol Lett 120:187-198.
33. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, and Nebert DW (2003) Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics 111:855-861.
34. Smolen TN, Brewer JA, and Weber WW (1993) Testosterone modulation of N-acetylation in mouse kidney. J Pharmacol Exp Ther 264:854-858.
35. Snyderwine EG, Yu M, Schut HA, Knight-Jones L, and Kimura S (2002) Effect of CYP1A2 deficiency on heterocyclic amine DNA adduct levels in mice. Food Chem Toxicol 40:1529-1533.
36. Stanley LA, Copp AJ, Pope J, Rolls S, Smelt V, Perry VH, and Sim E (1998) Immunochemical detection of arylamine N-acetyltransferase during mouse embryonic development and in adult mouse brain. Teratology 58:174-182.
37. Stanley LA, Mills IG, and Sim E (1997) Localization of polymorphic N-acetyltransferase (NAT2) in tissues of inbred mice. Pharmacogenetics 7:121-130.
38. Trepanier LA, Cribb AE, Spielberg SP, and Ray K (1998) Deficiency of cytosolic arylamine N-acetylation in the domestic cat and wild felids caused by the presence of a single NAT1-like gene. Pharmacogenetics 8:169-179.
39. Trepanier LA, Ray K, Winand NJ, Spielberg SP, and Cribb AE (1997) Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 54:73-80.
40. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, and Mulligan RC (1991) Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65:1153-1163.
41. Valentine JL, Lee SS, Seaton MJ, Asgharian B, Farris G, Corton JC, Gonzalez FJ, and Medinsky MA (1996) Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. Toxicol Appl Pharmacol 141:205-213.
42. Windmill KF, McKinnon RA, Zhu X, Gaedigk A, Grant DM, and McManus ME (1997) The role of xenobiotic metabolizing enzymes in arylamine toxicity and carcinogenesis: functional and localization studies. Mutat Res 376:153-160.
43. Wong FW, Chan WY, and Lee SS (1998) Resistance to carbon tetrachloride-induced hepatotoxicity in mice which lack CYP2E1 expression. Toxicol Appl Pharmacol 153:109-118.